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Fc-galactosylation of human 
immunoglobulin gamma isotypes 
improves c1q Binding and enhances 
complement-Dependent cytotoxicity
Benjamin Peschke1, Christian W. Keller1, Patrick Weber1, Isaak Quast1,2† and  
Jan D. Lünemann1,3*†
1 Institute of Experimental Immunology, Laboratory of Neuroinflammation, University of Zurich, Zurich, Switzerland, 
2 Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia, 
3 Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Binding of the complement component C1q to the CH2 domain of antigen-bound 
immunoglobulin gamma (IgG) activates the classical complement pathway and depends 
on its close proximity to Fc fragments of neighboring antibodies. IgG subclasses con-
tain a highly conserved asparagine 297 (N)-linked biantennary glycan within their CH2 
domains, the core structure of which can be extended with terminal galactose and sialic 
acid residues. To investigate whether Fc-glycosylation regulates effector functions of 
human IgG subclasses, we cloned the antigen-binding region of the CD20-specific 
monoclonal antibody rituximab into IgG isotype expression vectors. We found that 
Fc-galactosylation enhances the efficacy of CD20-targeting complement-fixing anti-
bodies for C1q binding and complement-mediated tumor cell lysis. Increased efficacies 
were restricted to IgG1 and IgG3 subclasses indicating that Fc-galactosylation alone 
is not sufficient for IgG2 and IgG4 to acquire complement-fixing properties. Addition of 
terminal galactose to the N-glycan specifically improved binding of C1q without chang-
ing antigen- and FcγRIIIa-binding affinities of IgG isotypes. These data indicate that Fc 
galactosylation can be harnessed to enhance the complement-activating properties of 
IgG1 and IgG3 antibodies.
Keywords: c1q, complement system proteins, antibodies, monoclonal, glycan, igg subclasses
inTrODUcTiOn
Immunoglobulin gamma (IgG) antibodies are preeminent effector proteins of the immune system. 
The bimodal architecture of IgG allows for simultaneous recognition of antigen (by the antigen-
binding fragment, Fab) and the initiation of IgG effector functions such as recruitment and activa-
tion of leukocytes and antibody-dependent cell-mediated cytotoxicity (ADCC) through interaction 
with FcγRs as well as complement activation through binding of the constant, crystallizable fragment 
(Fc) binding of C1q. Human IgG is subdivided in the four isotypes IgG1 to IgG4, numbered based on 
their abundance in serum (1). Despite being more than 90% identical in amino acid sequence, IgG 
isotypes differ in key functional regions responsible for flexibility, FcγR binding, and complement 
fixation (2).
All IgG subclasses contain a highly conserved asparagine-linked (N-)oligosaccharide located in 
the CH2 domain of the Fc region. Presence of this glycan serves important functions in protein 
FigUre 1 | Generation of degalactosylated and galactosylated immunoglobulin gamma (IgG) isotypes derived from rituximab. (a) Schematic depiction of an IgG 
antibody with its two Fc N-glycans (up) and detailed glycan composition of a fully galactosylated IgG-Fc N-glycan. (B) Gel electrophoresis and coomassie staining to 
detect total protein showing heavy and light chains of antibodies (up) and immunoblots using galactose- (Erythrina Cristagalli lectin) or mannose- (Lens Culinaris 
agglutinin) specific lectins.
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folding and post-translational quality control mechanisms and 
is essential for antibody-mediated effector functions (3, 4). The 
biantennary core glycan structure, which is composed of two 
N-acetylglucosamines (GlcNAc) and three mannose residues, 
can be further decorated with fucose, bisecting GlcNAc and 
terminal GlcNAc, galactose, and sialic acid. The highest degree 
of variability among IgG antibodies stems from the presence or 
absence of galactose with around 40% containing one galactose, 
20–40% two galactoses, and the remainder none (5–7).
Presence or absence of distinct N-glycan residues such as 
fucose and sialic acid can dramatically alter pro- and anti-
inflammatory IgG activities. Removal of the fucose residue 
from human IgG1 increases antibody-dependent cell-mediated 
cytotoxicity (ADCC) through improved affinity for Fcγ recep-
tor IIIa (FcγRIIIa) (8, 9). We have previously shown that IgG 
Fc sialylation of human monoclonal IgG1 molecules impairs 
their efficacy to induce complement-dependent cytotoxicity 
(CDC) (10). Here, we determined whether Fc galactosylation 
of human IgG isotypes (IgG1–4) regulates antibody effector 
functions.
resUlTs
generation of Degalactosylated and 
galactosylated igg isotypes  
Targeting cD20
To test the impact of Fc galactosylation of human IgG isotypes on 
target cell depletion, we first cloned the sequence encoding the 
heavy chain (HC) and light chain (LC) antigen-binding regions 
of the monoclonal CD20-targeting antibody rituximab into 
human IgG1–4 HC and kappa LC expression vectors. Plasmids 
were cotransfected in HKB11 cells and antibodies were purified 
from the supernatant using protein G columns. Next, we either 
treated the antibodies with recombinant galactosidase to com-
pletely remove galactose or with β-1,4-galactosyltransferase in 
the presence of uridine diphosphate (UDP-) galactose to obtain 
galactosylated antibodies. After repurification, antibodies were 
analyzed for purity and integrity by gel electrophoresis and 
immunoblotting with the galactose-specific Erythrina Cristagalli 
lectin to confirm the successful generation of glycovariants 
(Figure 1).
FigUre 2 | Fc-galactosylation does not increase CD20 binding of rituximab-derived IgG isotypes. Target antigen recognition by galactosylated and 
degalactosylated human IgG1–4 isotypes specific for CD20 analyzed by flow cytometry via titration on CD20+ Raji cells. MFI, median fluorescence intensity;  
IgG, immunoglobulin gamma.
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addition or removal of igg-Fc galactose 
Does not affect antigen Binding
Modifications in the Fc domain may change the structural 
properties of the antibody, potentially leading to changes in its 
antigen-binding region. To determine antigen-binding affinities 
of IgG isotype glycovariants, we titrated the antibodies on CD20 
expressing human Raji-Burkitt’s lymphoma cells and analyzed 
binding by flow cytometry (Figure 2). For each isotype, galacto-
sylated and degalactosylated glycovariants did not differ in their 
antigen-binding characteristics.
igg-Fc galactosylation of igg1 and igg3 
isotypes increases c1q Binding and 
complement-Dependent cytotoxicity
The efficacy of IgG isotype-derived glycovariants to induce 
complement-dependent cytotoxicity (CDC) was determined 
in Burkitt’s lymphoma-derived Raji cells in the presence of 
active complement (human serum). Rituximab-derived IgG3 
glycovariants showed the highest efficacy for CDC, followed by 
IgG1 (Figure  3). Glycovariants of IgG2 and IgG4 isotypes did 
not induce CDC. Galactosylation increased CDC mediated by 
both IgG1 (26% reduction of EC50) and IgG3 (13% reduction 
of EC50) but did not provide IgG2 and IgG4 with de novo ability 
to lyse target cells (Figure 3). To investigate the mechanism by 
which Fc-galactosylation impacts CDC, we determined the C1q 
binding affinities and kinetics of galactosylated and degalacto-
sylated antibody variants (10). Incubation of CD20-expressing 
Raji cells in the presence of human serum depleted for C5, an 
essential component of the complement cascade, which allows 
to analyze the binding of members of the complement cascade to 
target cells while preventing cell lysis (10), led to rapid binding 
of C1q (Figure  4). Fc-galactosylation substantially enhanced 
the antibodies’ capacity to bind C1q for IgG1 and IgG3 isotypes 
(Figure  4). These data indicate that the addition of terminal 
galactose to the Fc-glycan enhances cell-depleting efficacies of 
human IgG1 and IgG3 isotypes through increased C1q binding.
Fc-galactosylation Does not increase 
igg:Fcγriiia-Binding affinities
Rituximab depletes B  cells through a combination of CDC and 
antibody-dependent cell-mediated cytotoxicity (ADCC), which 
requires antibody binding to the human-activating FcγRIIIa 
(CD16) (10, 11). Absence of the IgG-Fc core fucose increases 
binding to FcγRIIIa (8, 12), a finding increasingly being used 
to improve the efficacy of therapeutic antibodies (13–15). Two 
studies reported that Fc-galactosylation results in a slight, albeit 
not statistically significant increase in FcγRIIIa-binding affinity 
and ADCC activity (16, 17). A more recent study confirmed 
that afucosylated glycoforms show higher binding affinities for 
FcγRIIIa, while Fc-galactosylation did not significantly impact 
FcγRIIIa binding (18). To investigate whether Fc-galactosylation 
of IgG isotype glycovariants increases binding affinities of IgG 
isotypes for FcγRIIIa, thereby potentially enhancing the anti-
bodies’ ability to induce ADCC, we titrated IgG glycovariants 
onto CHO-derived cell lines recombinantly expressing FcγRIIIa. 
FcγRIIIa binding was strongest for IgG1 and IgG3 isotypes 
FigUre 3 | Increased CDC of rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3 but not IgG2 and IgG4 upon Fc-galactosylation. Complement-
dependent lysis of CD20+ target cells in the presence of galactosylated or degalactosylated human anti-CD20 IgG isotypes. Exemplary lysis curves and EC50 values 
of three independent experiments are shown. Statistical analysis: paired two-tailed Student’s t-test *p < 0.05, **p < 0.01.
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(Figure  5). IgG-Fc galactosylation showed, however, no effect 
on FcγRIIIa-binding affinities for any of the IgG isotypes tested 
(Figure 5). Thus, while increasing the antibodies’ affinity for C1q 
binding and their efficacy to induce CDC, Fc-galactosylation did 
not change the affinity of human IgG isotypes for FcγRIIIa which, 
upon ligation, mediates ADCC.
DiscUssiOn
Initiation of the classical complement cascade trough binding 
of C1q is a potent proinflammatory mechanism by which IgG 
antibodies trigger immune responses during infection and its 
deregulation causes tissue damage in a wide array of human 
inflammatory, degenerative, and autoimmune diseases (19). Our 
study shows that Fc-galactosylation enhances the efficacy of com-
plement-fixing IgG isotypes to induce CDC through improved 
binding of C1q.
The antibody-dependent classical complement pathway is 
initiated if the C1 complex, formed by the multimeric pattern 
recognition molecule C1q and the modular proteases C1r and 
C1s, docks on antigen-bound IgG (20). C1q binds to monomeric 
IgG with very low affinity but antigen-driven antibody clustering 
allows for the formation of IgG hexamers that bind C1q with high 
avidity and promote efficient complement activation (21). The 
N-glycan resides in the CH2 domain, which is required for C1q 
binding (22). Sites on the surface of human IgG1 that constitute 
the C1q-binding epicenter are conserved in human IgG isotypes 
that are deficient in C1q binding and it has therefore been sug-
gested that the composition of the N-glycan might be critical for 
the antibodies’ conformation and its ability to bind C1q (23). 
Each biantennary oligosaccharide chain extends one arm toward 
the CH2–CH3 interface region and the other arm into the space 
between the CH2 domains, resulting in multiple interactions with 
the surface of the CH2 domain and the glycan of the opposing 
CH2 domain, respectively (4). Indeed, optimal C1 activation 
requires the presence of the Fc-glycan since C1q-mediated effec-
tor functions are compromised or lost in aglycosylated or degly-
cosylated IgGs (24–26). The effect of deglycosylation on reducing 
C1q binding has recently been attributed to its inhibition of IgG 
hexamerization via modulation of IgG Fc:Fc interactions rather 
than reduction of direct C1q-Fc-binding affinities (27). Based 
on these data and our results, we suggest that Fc-galactosylation 
modulates Fc:Fc interactions for antigen-bound IgG, thereby 
improving binding of C1q and increasing the antibodies’ ability 
to induce classical complement activation and CDC.
We systematically investigated whether Fc-galactosylation 
facilitates C1q binding and CDC effector functions across all 
human IgG isotypes. For murine IgG2b and IgG1, it has been 
demonstrated that addition of terminal galactose increases bind-
ing of C1q (28). While presence of terminal galactose enhanced 
complement activation by CD20 targeting, C1q-fixing human 
IgG1 and IgG3 isotypes, IgG2 and IgG4 remained deficient in 
initiating the classical complement cascade indicating that 
Fc-galactosylation alone is not sufficient for IgG2 and IgG4 to 
acquire complement-fixing properties.
Rituximab and therapeutic monoclonal antibodies (mAbs) 
that target tumor cells via ADCC or CDC are approved for the 
treatment of various cancers (29). B-cell depletion by CD20-
targeting antibodies is also widely used for the treatment of auto-
immune diseases (30). However, some patients do not sufficiently 
FigUre 4 | Increased C1q binding of Fc-galactosylated rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3. Kinetic of C1q binding to CD20+ Raji cells in 
the presence of galactosylated or degalactosylated glycovariants of human IgG1–4. Exemplary C1q-binding curves (left), flow cytometry histograms of C1q binding 
after 60 min (center) and statistics at time point 60 min of at least three independent experiments. Statistical analysis: unpaired two-tailed Student’s t-test, 
mean ± SEM, ns, not significant, *p < 0.05, **p < 0.01, and ***p < 0.001. MFI, median fluorescence intensity.
5
Peschke et al. Fc-Galactosylation Improves C1q Binding
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 646
FigUre 5 | Immunoglobulin gamma (IgG) binding to FcγRIIIa does not require Fc-galactosylation. Binding of galactosylated and degalactosylated IgG isotypes to 
CHO cells transfected with FcγRIIIa was analyzed by flow cytometry. Binding curves and flow cytometry histograms at 10 µg/ml are shown.
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respond to rituximab therapy (31, 32) and improved versions 
of B  cell depleting antibodies have been developed to increase 
ADCC activity and improve clinical efficacy (33, 34). Our data 
indicate that Fc-galactosylation, in addition to the established 
effect of defucosylation on ADCC, increases target cell cytotox-
icity through enhancing CDC. Fc-galactosylation specifically 
improved binding of C1q to human IgG1 and IgG3 without 
changing antigen-binding affinities. Our data therefore indicate 
that Fc-galactosylation should be harnessed in glycoengineering 
therapeutic antibodies for effective antibody-dependent comple-
ment activation and target cell killing.
MaTerials anD MeThODs
Buffers and reagents
Human serum complement (Cat. No.: A100; Lot No.: 035997) 
and C5-depleted human serum (Cat. No.: A501; Lot No.: 
031795) were purchased from Quidel® Corporation. Accutase 
was purchased from StemCell Technologies Inc. (Cat. No.: 
07920), Gibco™ RPMI-1640, HEPES (Cat. No.: 52400025), 
penicillin–streptomycin (P/S; 5,000 U/ml; Cat. No.: 15070063), 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Cat. No.: 
L34957), LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit 
(Cat. No.: L10119), and TO-PRO-3 Stain (Cat. No.: T3605) 
were purchased from Invitrogen. Fetal calf serum (FCS) was 
purchased from Sigma-Aldrich (Cat. No.: F7524-500M; Lot 
No.: 051M3395) and from Bioswisstech (Cat. No.: S0615; Lot 
No.: 1047D). β1-4 galactosidase (Cat. No.: 345806-50MIU) 
and UDP-galactose (Cat. No.: 670111-50MG) were pur-
chased from Merck Millipore Corporation, Calbiochem®. 
Protein-G sepharose was purchased from GE healthcare 
(Cat. No.: 17-0618-01). Biotinylated Erythrina Cristagalli lectin 
(Cat. No.: B-1145) and Lens Culinaris Agglutinin (Cat. No.: 
B-1045) were purchased from Reactolab. Phosphate-buffered 
saline (PBS; 2.68 mM KCl, 8 mM Na2HPO4, 1.8 mM KH2PO4, 
137 mM NaCl, pH adjusted to 7.3) was produced in-house.
antibodies and streptavidin
Monoclonal mouse anti-human C1q (Cat. No.: A201) and 
biotinylated anti-human C1q (Cat. No.: A700) were purchased 
from Quidel® Corporation. Polyclonal rabbit anti-mouse IgG 
(H +  L)-Alexa Fluor 488 (Cat. No.: A-11059) was purchased 
from Invitrogen. PE-conjugated streptavidin (Cat. No.: 405203) 
was purchased from Biolegend.
cDc assay
Raji cells were used as CD20+ target cells to assess CDC. 
Accordingly, 7 × 104 Raji cells were cultivated in RPMI-1640 con-
taining P/S (50 U/ml) in a humidified incubator (37°C, 5% CO2) 
in 96-well V-bottom plates. Cells were incubated with titrated con-
centrations of the respective galactosylated and degalactosylated 
anti-CD20 antibody isotypes. After 30 min, human serum comple-
ment was added to a final concentration of 5% and incubation was 
continued for another 12 h. Thereafter, cells were washed twice by 
adding 200 µl cold PBS and centrifugation at 400 × g and 4°C for 
5 min. Cells were resuspended in cold PBS and TO-PRO3 stain 
(final concentration of 200 nM) was added to detect dead cells. All 
samples were analyzed on a BD FACSCanto-II using FACSDiva 
v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.). Specific 
lysis was calculated as percent increase in dead cells compared to 
spontaneous lysis in the absence of an anti-CD20 antibody. EC50 
values were calculated via a non-linear regression in GraphPad 
Prism 5.
c1q-Binding assay
A total of 2 × 105 Raji cells were incubated with 10 µg/ml with 
galactosylated and degalactosylated anti-CD20 antibody isotypes 
in RPMI-1640 containing 1% P/S (50 U/ml) and 1% C5-depleted 
human serum for 5, 15, 30, or 60 min in a humidified incubator 
(37°C, 5% CO2). After incubation with the different anti-CD20 
antibody isotypes, cells were washed twice with 200 µl cold PBS, 
and C1q binding was determined by adding biotinylated anti-C1q 
antibody (25 µg/ml in PBS) for 1 h on ice followed by washing 
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twice with 200 µl cold PBS and incubation with PE-conjugated 
streptavidin (1:400 in PBS) and dead cell stain (LIVE/DEAD 
Fixable Aqua Dead Cell Stain Kit; 1:250 in PBS) for 20  min. 
After washing twice with 200 µl PBS, samples were analyzed on 
a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo 
software v9.3.1 (Tree Star Inc.).
cD20-Target-Binding assay
Raji cells were maintained in RPMI-1640 containing P/S 
(50  U/ml) and 10% FCS in a humidified incubator (37°C, 5% 
CO2). 1.2 × 105 Raji cells and anti-CD20 antibody isotypes and 
glycovariants were incubated for 25 min on ice. Dead cells were 
excluded using LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit. 
Cells were washed twice with 200  µl PBS and anti–mouse IgG 
(H + L)-Alexa Fluor 488 was added and incubated for 20 min 
on ice followed by two washing steps with 200 µl cold PBS. All 
samples were analyzed on a BD FACSCanto-II using FACSDiva 
v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.).
Fcγr-Binding assay
Human FcγRIIIa-expressing CHO cells (35) were kindly provided 
by Falk Nimmerjahn (Department of Biology, University of 
Erlangen-Nürnberg, Germany). Cells were maintained in RPMI-
1640 containing P/S (50  U/ml) and 10% FCS in a humidified 
incubator (37°C, 5% CO2). To detect binding of anti-CD20 anti-
bodies, cells were detached using accutase, washed with cold PBS, 
and 2 × 105 cells were incubated on ice for 30 min with anti-CD20 
antibodies. After incubation, cells were washed twice with 200 µl 
cold PBS and anti-mouse IgG (H + L)-Alexa Fluor 488 was added 
for 20 min on ice. All samples were washed twice with 200 µl cold 
PBS and analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 
software and FlowJo software v9.3.1 (Tree Star Inc.).
generation of recombinant Monoclonal 
anti-cD20 igg isotypes
The DNA encoding for the N terminal region of the light chain 
(amino acids QIVLS until KLEIK) and heavy chain (amino acids 
QVQLQ until TVSAA) of rituximab (www.drugbank.ca; accession 
number DB00073) was synthesized by Invitrogen GeneArt gene 
synthesis. The N terminal region of the light chain was cloned into 
the multiple cloning site (MCS) of Igκ-AbVec (NCBI GenBank 
accession number FJ475056.1) using AgeI and BsiWI as previ-
ously described (36). To obtain human IgG-1, -2, -3 and -4 heavy 
chain expression vectors IgG-AbVec (NCBI GenBank accession 
number FJ475055.1) (36) was modified to encode for human IgG1 
(allotype G1m17,1), IgG2 (allotype G2m), IgG3 (allotype G3m), 
and IgG4 (kindly provided by Lars Hangartner, the Scripps 
Research Institute, Department of Immunology and Microbial 
Science, La Jolla, CA, USA) (2, 37, 38). The N terminal region of 
the rituximab heavy chain was cloned into the MCS using AgeI 
and SalI as previously described (36). Recombinant monoclonal 
antibodies were expressed and purified as previously described 
(10, 32, 39). Briefly, heavy and light chain expression plasmids 
were cotransfected into a human B cell–epithelial cell fusion cell 
line (HKB11) supporting high-level recombinant protein expres-
sion (40) using calcium phosphate-mediated transfection. After 
6 days, antibodies were purified from cell culture supernatants 
by binding to a protein G column and elution with 0.1 M glycine 
(pH 2) followed by neutralization with 1  M Tris pH 8.8 and 
dialysis to PBS. Antibody purity and integrity were confirmed 
by polyacrylamide gel electrophoresis, coomassie brilliant blue 
staining and Western blotting with isotype-specific monoclonal 
antibodies.
generation of galactosylated and 
Degalactosylated antibody glycovariants
Antibody glycovariants were generated as previously described 
(10, 39). For removal of galactose, antibodies were dialyzed to 
50 mM sodium phosphate buffer pH 6.0, 60 mU β1–4 galactosi-
dase was added per mg of antibody and the reaction was incu-
bated for 6 h at room temperature followed by 1 h at 37°C. To add 
galactose, antibodies were dialyzed to 0.2 M MES pH 6.5 followed 
by the addition of 10 mM MnCl2, UDP-galactose, 0.02% NaN3, 
and 5 µg recombinant β1–4 galactosyltransferase [produced in-
house (39)]. The reaction was incubated at 37°C for 48 h. Finally, 
all antibodies were centrifuged for 2 h at 4°C and >20,000 × g to 
remove aggregates, repurified by gravity-flow protein-G sepha-
rose columns, and dialyzed to PBS. Successful degalactosylation 
and galactosylation were monitored by lectin-blotting using the 
galactose-specific lectin from Erythrina Cristagalli.
statistics
A p-value of 0.05 or less was defined as statistically significant. For 
all analyses, Prism software, version 5 (GraphPad Software, Inc.) 
was used. Specific statistical tests are indicated in the respective 
figure legends.
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